Israeli Venture Capital Firm Joins Israel-based Alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, BioMed X and Amazon Web Services

以色列风险投资公司加入以色列阿斯利康、默克、辉瑞、梯瓦、以色列生物技术基金、BioMed X和亚马逊网络服务联盟

REHOVOT, Israel, Jan. 8, 2024 /PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel.

以色列雷霍沃特（REHOVOT），2024年1月8日/PRNewswire/--爱恩实验室（AION Labs）是同类风险工作室中首家率先采用人工智能技术和计算科学来解决治疗挑战的公司，今天宣布与以色列领先的早期风险投资公司之一Amiti Ventures建立新的战略伙伴关系。

The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups..

该合作关系进一步加强了制药、生物技术和技术投资领域全球领导者的联盟，扩大了其作为风险工作室和新创企业合作伙伴的服务范围。。

'With a proven track record of identifying the best teams for the mission and investing early in the most innovative deep tech startups that shape the future, Amiti Ventures will bring important complementary capabilities and expert investor knowledge to the AION Labs partnership,' said Mati Gill, CEO of AION Labs.

爱恩实验室首席执行官马蒂·吉尔（MatiGill）说，阿米提风险投资公司（AmitiVentures）拥有为此次任务确定最佳团队和早期投资塑造未来的最具创新性的深度科技初创公司的良好记录，将为爱恩实验室合作伙伴关系带来重要的补充能力和专家投资者知识。

'We thank Amiti for its vote of confidence in our model of innovation for groundbreaking AI and computational biotech ventures. We further appreciate Amiti's recognition that Israel's ecosystem is poised to lead the world in bringing AI and biotech together to solve our biggest drug discovery challenges.'.

“我们感谢阿米蒂对我们开创性人工智能和计算生物技术风险投资的创新模式投下的信任票。我们进一步感谢阿米蒂认识到以色列的生态系统将引领世界，将人工智能和生物技术结合在一起，解决我们最大的药物发现挑战。”。

By joining forces with Amiti, AION Labs is enhancing its expertise and capabilities in the deep tech and computational technology domains, areas that are critical to the success of biotech innovation. Amiti's extensive experience and track record in these fields will bring invaluable investor knowledge and insights to AION Labs, enabling it to more effectively develop and support early-stage startups focused on AI and computational biology.

通过与Amiti的合作，爱恩实验室正在加强其在深层技术和计算技术领域的专业知识和能力，这些领域对生物技术创新的成功至关重要。Amiti在这些领域的丰富经验和业绩记录将为AION实验室带来宝贵的投资者知识和见解，使其能够更有效地开发和支持专注于AI和计算生物学的早期初创公司。

Amiti's first investment in the venture studio will entail investment in DenovAI Biotech's Seed round of funding. Launched in 2022, DenovAI is developing an AI-powered biophysics solution for de novo antibody and protein design..

阿米蒂对风险工作室的首次投资将意味着对德诺瓦伊生物技术公司（DenovAI Biotech）种子轮融资的投资。DenovAI于2022年推出，目前正在开发一种人工智能驱动的生物物理解决方案，用于从头抗体和蛋白质设计。。

AION Labs builds and invests in early-stage startup teams focused on AI and computational biology in drug discovery and development, offering them top-notch resources and mentorship while working closely with them to develop new technologies that meet the most significant challenges in the pharmaceutical industry.

AION实验室建立并投资于早期创业团队，专注于药物发现和开发中的人工智能和计算生物学，为他们提供一流的资源和指导，同时与他们密切合作开发新技术，以应对制药行业最重大的挑战。

The partnership with Amiti Ventures will help AION Labs to advance healthcare towards patient-centric precision medicine and create a significant contribution to the health and well-being of humankind by helping to bring new treatments to market faster and more efficiently..

与Amiti Ventures的合作将有助于AION实验室推动医疗保健朝着以患者为中心的精准医学方向发展，并通过帮助更快、更有效地将新疗法推向市场，为人类的健康和福祉做出重大贡献。。

'We believe that AION Labs is uniquely positioned to identify the biggest challenges to accelerate drug discovery and development and then evaluate the best computational bio approaches and entrepreneurs,' said Ben Rabinowitz, Founder and Managing Partner of Amiti Ventures. 'AION Labs' venture studio model bridges the gap between outstanding academic research, huge leaps forward in generative AI, and the biggest challenges and opportunities in the development of new medicines, and we look forward to working closely with our new partners to make this a reality..

Amiti Ventures创始人兼管理合伙人本·拉比诺维茨（BenRabinowitz）说：“我们相信，爱恩实验室具有独特的优势，能够确定加速药物发现和开发的最大挑战，然后评估最佳的计算生物方法和企业家。”爱恩实验室的风险工作室模式弥合了杰出的学术研究、生成人工智能的巨大飞跃以及新药开发中最大的挑战和机遇之间的差距，我们期待着与新合作伙伴密切合作，使之成为现实。。

'We also have been amazed by the can-do spirit of the AION Labs team,' added Rabinowitz. 'It is that readiness to create, pull themselves up by the bootstraps and forge ahead with amazing innovation that makes AION and Israel's entire startup ecosystem so special.'

拉比诺维茨补充道：“我们也对爱恩实验室团队的能干精神感到惊讶。”正是这种创造、自力更生和开拓创新的意愿，使爱恩和以色列的整个创业生态系统如此特殊。”

About AION Labs

关于AION实验室

AION Labs is a first-of-its-kind alliance of Astrazeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and Amazon Web Services (AWS), powered by BioMed X with the support of the Israeli Government via the Israel Innovation Authority, that have come together with one clear mission: to create and adopt groundbreaking new AI technologies that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide..

爱恩实验室是阿斯利康、默克、辉瑞、梯瓦、以色列生物技术基金、阿米迪风险投资公司和亚马逊网络服务（AWS）的首家同类联盟，由BioMed X提供支持，以色列政府通过以色列创新局提供支持，这带来了一个明确的使命：创造和采用开创性的新人工智能技术，改变药物发现和开发过程，为全世界所有人的健康和福祉做出贡献。。

AION Labs is a unique venture hub where brilliant innovators and scientist-founders convene from around the world to solve the biggest R&D challenges guided by years of accumulated know-how, data and experience in pharma. The lab leverages its partners' wealth of knowledge and a new multidisciplinary mindset with the ingenuity, agility and innovative power of Israel's startup ecosystem, to develop strong companies with clear long-term strategies, that will pave the way to the future of healthcare.

爱恩实验室（AION Labs）是一个独特的风险投资中心，世界各地杰出的创新者和科学家创始人聚集在这里，以多年积累的制药专业知识、数据和经验为指导，解决最大的研发挑战。该实验室利用其合作伙伴的丰富知识和新的多学科思维，以及以色列创业生态系统的独创性、灵活性和创新能力，发展具有明确长期战略的强大公司，为医疗保健的未来铺平道路。

AION Labs cultivates innovation from within; its unique venture creation process bridges the gap between outstanding academic research in the field of AI and the biggest R&D needs in the discovery and development of new medicines for the benefit of patients..

爱恩实验室从内部培养创新；它独特的创业过程弥合了人工智能领域杰出的学术研究与为患者发现和开发新药的最大研发需求之间的差距。。

For more information, visit aionlabs.com.

有关更多信息，请访问aionlabs.com。

Follow AION Labs on LinkedIn and X.

在LinkedIn和X上关注AION实验室。

About Amiti Ventures

关于Amiti Ventures

Amiti is a leading Israeli deep tech venture capital firm focused on finding seed stage outlier companies developing transformational technologies. Amiti's edge is identifying the best deep tech founders that have the potential to disrupt and dominate major markets. Amiti targets quantum computing and computational and synthetic biology, where Israel has some of the most promising founders, expertise and multi-disciplinary skills in the world..

Amiti是以色列领先的深度科技风险投资公司，专注于寻找开发转型技术的种子期异常公司。Amiti的优势在于确定最优秀的深层技术创始人，这些创始人有可能扰乱和主导主要市场。Amiti的目标是量子计算、计算和合成生物学，以色列拥有世界上一些最有前途的创始人、专业知识和多学科技能。。

For more information, visit www.amiti.vc.

有关更多信息，请访问www.amiti.vc。

Media Contact

媒体联系人

FINN Partners for AION LabsDanny Sudwarts[email protected]  (+1) 469-297-2515

AION LabsDanny Sudwarts的FINN Partners[受电子邮件保护]（+1）469-297-2515

Logo - https://mma.prnewswire.com/media/1708278/AION_Labs_Logo.jpg

徽标-https://mma.prnewswire.com/media/1708278/AION_Labs_Logo.jpg

SOURCE AION Labs

来源AION实验室